HOYA, Adoptics partner to develop shape-changing accommodating intraocular lens

HOYA announced today that the Company has formed a strategic partnership with Adoptics (Switzerland) through an investment that will fund the development of a shape-changing accommodating intraocular lens (AIOL).

“This AIOL technology is based on a novel and clever concept that has the potential to produce a very powerful accommodative effect - something which remains the 'Holy Grail' of cataract and refractive surgery.”

Dr. David F. Chang, a clinical professor of ophthalmology at the University of California, San Francisco, commented, "This AIOL technology is based on a novel and clever concept that has the potential to produce a very powerful accommodative effect - something which remains the 'Holy Grail' of cataract and refractive surgery."

Commenting on the investment, Tom Dunlap, President and CEO of HOYA Surgical Optics, stated, "HOYA recognizes the significant impact that the proprietary AIOL technology will have in addressing both the presbyopic and myopic challenges of patients with cataracts. We believe the shape-changing AIOL is the most efficient and consistent way to provide the power range necessary for true accommodation and to achieve spectacle-free vision for many patients."

Adoptics' Founder and CEO, Dr. Khalid Mentak, stated, "This strategic partnership with HOYA will help us bring to market the first shape-changing accommodating IOL that closely mimics the mode of action of young crystalline lenses. Adoptics' technology uses a proprietary fluid-based refraction system within an IOL to create significant changes in the refractive power of the human visual system. Unlike other presbyopia-correcting IOLs, the Adoptics lens does not require movement of the optic within the eye to change refractive power. The refractive surface of the IOL itself changes shape in response to movement of the ciliary muscles, the natural process of accommodation in the human eye."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pre-surgery chemotherapy shows promise for preserving vital organs in nasal and sinus cancer